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Background: Endogenous estrogens may play a vital role in colorectal tumorigenesis. Estrogen receptor beta is the
predominant subtype which mediates the biological effect of estrogens, while loss of expression of estrogen
receptor beta has been indicated as a common step in the development of colorectal cancer (CRC).
Epidemiological studies have revealed several functional polymorphisms of estrogen receptor beta (ESR2) for cancer
risk, but relevant study in CRC is limited, particularly in men. This study aimed to investigate the association of
circulating estradiol and variations of ESR2 with CRC risk in men.
Methods: We initiated a case–control study consisting of 390 patients with CRC and 445 healthy controls in men
only. We genotyped ESR2 single nucleotide polymorphisms (SNPs) rs1256049 and rs4986938 and measured serum
estradiol concentration using chemilluminescence immunoassay. Multivariable logistic regression model was
performed to evaluate the associations between these variables and CRC risk.
Results: ESR2 rs1256049 CT/TT genotypes were associated with reduced risk of CRC (odds ratio [OR], 0.7, 95%
confidence interval [CI], 0.5–1.0), while rs4986938 CT/TT genotypes were associated with increased risk of CRC (OR,
1.5, 95% CI, 1.0–2.1). In addition, the CRC risk increased with the number of risk genotypes of these two SNPs in a
dose–response manner (Ptrend, 0.003). Specifically, subjects carrying risk genotypes of both SNPs had the highest risk
of CRC (OR, 2.0, 95% CI, 1.3–3.3.). Moreover, serum estradiol concentration alone was associated with risk of CRC in
men (OR, 1.2, 95% CI, 1.0–1.3). However, individuals presenting both rs4986938 CT/TT genotypes and high level of
serum estradiol had a high risk of CRC (OR, 2.3, 95% CI, 1.4–3.9), compared with those presenting CC genotype and
low level of serum estradiol. The similar joint results were not observed for SNP rs1256049.
Conclusions: These results suggest that endogenous estrogen and genetic variations in ESR2 may individually, or
more likely jointly, affect CRC risk in male Han Chinese population, while larger studies are needed to validate our
findings.
Keywords: Colorectal cancer, Endogenous estrogen, Estrogen receptors, Single nucleotide polymorphisms* Correspondence: tjchenxp@gmail.com; yxl@medmail.com.cn
†Equal contributors
1Department of Oncology, Tongji Hospital, Huazhong University of Science
and Technology, 1095 Jiefang Ave, Wuhan 430030, Hubei, China
2Department of Surgery, Tongji Hospital, Huazhong University of Science and
Technology, 1095 Jiefang Ave, Wuhan 430030, Hubei, China
Full list of author information is available at the end of the article
© 2012 Wu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Wu et al. BMC Cancer 2012, 12:276 Page 2 of 8
http://www.biomedcentral.com/1471-2407/12/276Background
Colorectal cancer (CRC) is a major health problem in
China and worldwide. With more than one million new
cases diagnosed and more than 500,000 deaths each year,
it has become the third most common cancer and the
fourth most common cause of cancer death globally
[1,2]. In addition to smoking, alcohol drinking, dietary
factors and obesity, estrogens appear to play a role in
CRC carcinogenesis [3-5]. Inherited predisposition may
also influence CRC development [1].
While typically referred to as female hormone, estro-
gens regulate a board range of important functions in
both females and males. Estrogen induction of cell pro-
liferation has been considered as a critical step in car-
cinogenesis of gynecologic tissues including breast,
endometrium and ovary, and also has been suggested to
involve in cancer of colon and prostate [6]. An emerging
body of evidence supports that endogenous and exogen-
ous estrogens may play different roles in colorectal
tumorigenesis[7]. For instance, the Women’s Health
Initiative (WHI) study observed reduced CRC rates by
37% in postmenopausal women receiving estrogen-plus-
progestin formulations compared to those receiving
placebos, and several studies have reported similar
observations [8-12]. In contrast, two prospective studies
reported that high concentrations of circulating estrogen
conferred increased risk for CRC [13,14]. It is noted,
however, that all the studies published used women only
as the study subjects. The correlation between endogen-
ous estrogen and the risk of CRC in men has not yet
been evaluated.
The biological effects of estrogens are mediated by
estrogen receptors (ER) α and β, which belong to the
nuclear hormone receptor superfamily and act as ligand-
activated transcription factors [15]. ERβ is the predomin-
ant subtype of estrogen receptor in colorectal epithelial
cells; its loss of expression has been indicated as a com-
mon step in the development of CRC [6,16-18]. ERβ is
encoded by estrogen receptor β (ESR2) gene, which is
located on chromosome 14q23.2 and covers a genomic
region of 111.5 kb [19]. Several ESR2 genetic variants
have been investigated, including rs1256049 in exon 5,
which causes a synonymous change of unknown func-
tional significance, and rs4986938, which is located in
the 3′-untranslated region of the ESR2 gene [20,21]. Both
rs1256049 and rs4986938 have been associated with a
number of diseases, including breast cancer, endometrial
cancer, prostate cancer, reduced bone mineral density,
and cardiovascular disease [22-28]. Only few studies
attempted so far to evaluate the ESR2 polymorphism in
cancer of colon and rectum and reported conflicting
results [25,29].
Given the potential roles of estrogens in CRC and the
importance of ERβ in estrogen function, we hypothesizedthat endogenous estrogen level and ESR2 genetic varia-
tions may individually, or more likely jointly, be associated
with the risk of CRC in men. We therefore conducted this
male only case–control study to examine the role of
functional ESR2 SNPs rs1256049 and rs4986938 and cir-
culating concentrations of estradiol in CRC risk.
Methods
Study population
The present study included a total of 835 unrelated male
subjects, of which 390 were patients with CRC and 445
were controls. Among patients with CRC, 168 were
recruited between 2008 and 2011 from Tongji Hospital,
which is affiliated with Tongji Medical College, and 222
were recruited between 2009 and 2011 from Wuhan
Eighth Hospital. These two hospitals were chosen be-
cause they are the regional reference center for CRC
treatment. Biopsy evaluation was performed in each case
and the final diagnosis was confirmed by histopathology.
The controls are healthy volunteers recruited from
Tongji Hospital Physical Center during the same period
who received a comprehensive health examination. The
exclusion criteria for both cases and controls included 1)
age less than 15 years at the time of diagnosis (cases) or
recruitment (control); 2) previous history of malignan-
cies; 3) history of inflammatory bowel disease including
familial adenomatous polyposis, ulcerative colitis, and
Crohn’s disease; 4) history of chronic hepatic, renal and
endocrine disease; 5) family history of CRC; 6) currently
taking medication which was known to influence sex
hormone level, and 7) diagnosed with hypertension and
diabetes mellitus, which could affect sex hormone level.
In addition, those who had gastrointestinal pain, detec-
tion of blood in stool, or currently diagnosed with com-
municable diseases such as tuberculosis and acquired
immune deficiency syndrome were excluded from the
control group. The cases and controls were from the
same geographic region and limited to Han Chinese
ethnicity.
Eligible participants were interviewed in person to col-
lect demographic and exposure information including
smoking and alcohol drinking status (response rate
98%). Participants who have smoked more than 100
cigarettes in their lifetimes were classified as ever-
smokers; the others were classified as never-smokers.
Participants who have drunk alcohol beverage at least
once a week for more than one year were classified as
ever-drinkers; the others were classified as never-
drinkers.
The study conformed to guidelines set forth by the
Declaration of Helsinki and was approved by the ethics
committee of the Tongji Medical College. Written
informed consent was obtained from each participant
before recruitment.
Table 1 Selected demographic characteristics of
colorectal cancer cases and controls
Controls (n = 445) Cases (n = 390)
Characteristics n % n % P-valuea
Age, years
≤ 48 239 53.7 82 21.0 <0.001
>48 206 46.3 308 79.0
Smoking status
Ever 283 63.6 181 46.4 <0.001
Never 162 36.4 209 53.6
Alcohol drinking Status
Ever 292 65.6 137 39.0 <0.001
Never 153 34.4 214 61.0
aP values were calculated from chi-square test.
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Peripheral blood samples were collected from all partici-
pants. Genomic DNA was extracted from peripheral
blood using a FUJI whole blood DNA kit (Fujifilm Cor-
poration, Japan). All participants were genotyped for
rs1256049 and rs4986938 polymorphisms using a Taq-
man SNP genotyping assay implemented by the ABI
Prism 7900HT Sequence Detection System (Applied
Biosystems). Primer and probe sequences were opti-
mized using the SNP assay design service provided by
Applied Biosystems. For each SNP, the call rate was
more than 98%. To verify the accuracy of Taqman geno-
typing results, 5% of the samples were randomly selected
and genotyped using the direct-sequencing method with
a concordance of no less than 99%.
Analysis of serum estrogen concentration
Endogenous estrogens are a group of steroidal com-
pounds including 17b-estradiol, estrone, and estriol. Be-
cause the bioactivity of 17b-estradiol is the greatest of
the three in vivo [30], we chose to evaluate estradiol
concentration in serum. Estradiol concentrations were
measured using blood samples collected at the initial
visit. The blood samples were centrifuged at 1300 g for
10 minutes, and the separated sera were stored at −70 °C
within 2 hours of blood collection.
Because some samples did not have enough serum for
measurement, estradiol concentrations were available
from 359 male patients and 378 male controls. The de-
tection rate was 99%. Participants having no estradiol
data were not significantly different from participants
having estradiol data in regard to age, gender, smoking,
or drinking status (data not shown). Using 300 μl of
available serum, estradiol concentrations (in pictograms
per milliliter) were quantified using sensitive in vitro es-
tradiol diagnostic kits (the normal male adult reference
value is 20–75 pg/ml) (chemiluminescence immuno-
assay, Beckman Coulter Inc., USA). Laboratory per-
sonnel were blinded to case status. The samples were
analyzed in random order, and approximately 5% of the
samples were repeated with a 100% concordance.
Statistical analysis
The distributions of demographic and exposure charac-
teristics among the cases and controls were compared
with Pearson chi-square test. For each ESR2 SNP, devi-
ation from Hardy-Weinberg equilibrium was assessed by
chi-square test in controls. Multivariable logistic regres-
sion model, with adjustment for potential confounding
factors, was used to calculate odds ratios (ORs) and 95%
confidence intervals (CIs) for genotype-specific cancer
risk. In addition, we conducted subgroup analyses strati-
fied by age, smoking status and alcohol drinking status
to examine the genotype-specific cancer risk in eachsubgroup. Cut-off of age was based on the median age
among controls. The significance of the interactions was
determined by a likelihood ratio test comparing a full
model including the interaction term with the main ef-
fect model.
The levels of estradiol in male cases and male controls
were compared using multivariable logistic regression
model adjusted for age. A square-root transformation
was applied to the estradiol concentration. We also
assessed the joint association of estradiol level and ESR2
rs1256049 and rs4986938 genotypes with CRC risk by
multivariable logistic regression model. For serum estra-
diol, the mean estradiol level in all male subjects (includ-
ing cases and controls) was used as the grouping
standard: higher than average concentration was defined
as high estradiol level and lower than or equal to average
concentration was defined as low estradiol level.
All statistical tests were 2-sided, and a P value less
than 0.05 was considered to be statistically significant.
All analyses were performed using SAS software, version
9.2 (SAS Institute Inc., Cary, NC, USA).Results
Characteristics of participants
Table 1 depicts distributions of selected characteristics
of male only patients with CRC and controls. Cases were
older, more likely to be never-smokers and never-
drinkers than controls in this study. The average age
(standard deviation [SD]) at diagnosis of CRC was 58.3
(13.3) years (median, 58 years) in these patients. The
average age (SD) at recruitment was 50.0 (9.4) years
(median, 48 years) in the healthy controls.Genotype specific risk association analyses
Two ESR2 SNPs, rs1256049 and rs4986938, were geno-
typed. Among controls, genotype distributions were in
Table 2 ESR2 genotype frequencies in colorectal cancer





Genotypes n % n % ORb (95% CI) P-valueb
rs1256049
CC (Ref.c) 167 37.9 168 43.9 1.0 0.029
CT/TT 274 62.1 215 56.1 0.7 (0.5–1.0)
rs4986938
CC (Ref.c) 349 79.9 277 71.8 1.0 0.036




232 53.2 165 43.4 1.0 0.014
1 risk genotype 156 35.8 154 40.5 1.3 (0.9–1.8)




232 53.2 165 43.4 1.0 0.016
With risk genotype 204 46.8 215 56.6 1.5 (1.1–2.0)
a The genotype frequencies in controls were in Hardy-Weinberg equilibrium
(P= 0.686 for rs1256049 and P= 0.669 for rs4986938, Chi-square test).
bORs and P values were calculated using unconditional logistic regression
model adjusted for age, smoking status and alcohol drinking status.
cRef. = reference group.
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and P= 0.669 for rs4986938).
Table 2 shows the genotype specific risks of CRC in
the studied population: compared to the homozygousTable 3 Stratification analysis of colorectal cancer risk associa
rs1256049
CC (Ref.a) CT/TT
Subgroups Ca/Cob Ca/Cob ORc (95%
Age, years
≤ 48 30/88 50/150 1.0 (0.5–1
>48 138/79 165/124 0.7 (0.5–1
Pinteraction 0.483
Smoking status
Ever 88/104 87/175 0.5 (0.4–0
Never 80/63 128/162 1.0 (0.6–1
Pinteraction 0.061
Alcohol drinking status
Ever 66/112 66/178 0.6 (0.4–1
Never 89/123 55/96 0.8 (0.5–1
Pinteraction 0.473
aRef. = reference group.
bCa/Co = colorectal cancer cases/controls.
cORs were calculated using unconditional logistic regression model adjusted for agCC genotype, CT/TT genotypes of rs1256049 and
rs4986938 were associated with significant reduced and
increased risk of CRC, respectively. Similarly, under log-
additive model, risk estimates were 0.8 (95% CI, 0.6–1.0)
for rs1256049 and 1.5 (95% CI, 1.0–2.0) for rs4986938.
No significant association was found for codominant
model (data not shown).
In order to assess the joint effect of these polymorph-
isms on CRC risk in men, we categorized all subjects
into 3 groups based on the number of risk genotypes
which were determined on the basis of the risk estimates
in Table 2. The risk genotypes were rs1256049 CC geno-
type and rs4986938 CT/TT genotypes. We also dichoto-
mized patients into groups with and without risk
genotype. As shown in Table 2, subjects with risk geno-
type had a significantly increased risk of CRC compared
with those carrying no risk genotype (OR, 1.5, 95% CI,
1.1–2.0). Specifically, subjects carrying risk genotype of
both polymorphisms had the highest risk of developing
CRC (OR, 2.0, 95% CI, 1.3–3.3). We also found the CRC
risk in men increased with the number of risk genotype
in a dose–response manner (Ptrend, 0.003). Additionally,
we evaluated the combined effect of risk alleles of
rs1256049 and rs4986938 and found increased risk for
CRC associated with cumulative number of risk alleles
(OR, 1.3, 95% CI, 1.1–1.6, P, 0.003).Stratification analysis
The genotype specific risks of CRC stratified by age,
smoking and alcohol drinking status are shown in
Table 3. The protective effect of rs1256049 CT/TTted with ESR2 genotypes
rs4986938
CC (Ref.a) CT/TT
CI) Ca/Cob Ca/Cob ORc (95% CI)
.8) 55/186 27/49 1.4 (0.7–2.7)
.0) 222/163 82/39 1.5 (0.9–2.3)
0.831
.8) 139/226 40/53 1.0 (0.6–1.7)
.6) 138/123 69/35 2.2 (1.3–4.0)
0.058
.0) 100/229 34/57 1.6 (0.9–2.7)
.2) 148/120 66/31 1.5 (0.9–2.4)
0.651
































Figure 1 Serum estradiol concentration in male colorectal
cancer cases and controls. The dots, error bars and upper and
lower ends of the box represent outliers, spread, and first and third
quartiles, respectively. The line the box represent median.
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ever-smokers and ever-drinkers: rs1256049 CT/TT gen-
otypes were associated with significantly reduced risk of
CRC in >48 years old subjects (OR, 0.7, 95% CI, 0.5–
1.0, P, 0.047), in ever-smokers (OR, 0.5, 95% CI, 0.4–0.8,
P, 0.005), and in ever-drinkers (OR, 0.6, 95% CI, 0.4–1.0,
P, 0.038), after adjustment for potential confounding fac-
tors, while no significant interaction was found with age,
smoking status and alcohol drinking status. For
rs4986938, the ORs for CT/TT genotypes compared to
CC genotype were significant for never-smokers only
(OR, 2.2, 95% CI, 1.3–4.0, P, 0.005).Table 4 Joint effect of serum estradiol level and ESR2 genoty
Controls (n = 378)
Variables n %
Estradiol + rs1256049
Low CT/TT 127 33.8
CC 80 21.3
High CT/TT 109 29.0
CC 60 16.0
Estradiol + rs4986938
Low CC 162 43.4
CT/TT 42 11.3
High CC 136 36.5
CT/TT 33 8.9
aORs were calculated using unconditional logistic regression model adjusted for ag
bORs were calculated using unconditional logistic regression model adjusted for agSerum estradiol concentrations in male patients with CRC
and controls
As illustrated in Figure 1, we observed higher levels of
serum estradiol in cases than in controls. Mean (SD) es-
tradiol concentrations were 39.55 (16.25) pg/ml in male
patients with CRC and 37.45 (15.86) pg/ml in male con-
trols. Serum estradiol levels were significantly associated
with increased risk of CRC in men after adjustment for
age; the adjusted OR for serum estradiol levels (continu-
ous) was 1.2 (95% CI, 1.0–1.3, P, 0.009).
Joint association of estradiol level and ESR2 genotypes
with the risk of CRC
In Table 4, we combined the estradiol levels and ESR2
genotypes to estimate their joint effect on risk of male
CRC using two models, one adjusted only for age, and
another adjusted for potential risk factors of CRC in-
cluding age, smoking and alcohol drinking status. Using
the group of individuals with rs4986938 CC genotype
and low level (≤38.47 pg/ml) of estradiol as reference
group, the group of individuals with CT/TT genotypes
and high level (>38.47 pg/ml) of estradiol had the high-
est OR of 2.3 (95% CI, 1.4–3.9) after adjusted for age
among all subgroups. Such an association was weakened
but remained in the same direction after further adjust-
ment with other factors including smoking and alcohol
drinking status (OR, 1.6, 95% CI, 0.9–2.9). However, the
associations of such combined serum estradiol and ESR2
genotypes with CRC risk were almost similar among
those subgroups for rs1256049.
Discussion
To the best of our knowledge, the present study is the
first to explore the potential role of endogenous estrogen
on risk of CRC in men. We found serum estradiol level
to be positively associated with increased risk of CRC inpes on colorectal cancer risk in men
Cases (n = 359)
n % ORa (95% CI) ORb (95% CI)
96 27.3 1.0 1.0
87 24.7 1.6 (1.0–2.4) 1.7 (1.1–2.6)
101 28.7 1.5 (1.0–2.3) 1.2 (0.8–1.9)
68 19.3 1.6 (1.0–2.5) 1.4 (0.8–2.3)
144 40.6 1.0 1.0
43 12.1 1.1 (0.7–1.9) 1.1 (0.6–1.9)
113 31.8 1.0 (0.7–1.4) 0.8 (0.6–1.2)
55 15.5 2.3 (1.4–3.9) 1.6 (0.9–2.9)
e.
e, smoking status and alcohol drinking status.
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ship between ESR2 rs1256049 and rs4986938 and risk of
CRC in Han Chinese and found both SNPs were asso-
ciated with susceptibility to CRC in men. We observed a
significant association between the risk genotypes of
these two SNPs in combination and CRC risk, which
was statistically significant in a dose–response manner.
In addition, men possessing the risk genotypes of
rs4986938 and high level of serum estradiol had signifi-
cant increased risk for developing CRC.
The role of estrogens in CRC risk remains controver-
sial. In the WHI trial, postmenopausal women who ran-
domly assigned to combination of estrogen plus
progestin therapy group were at reduced risk for CRC
compared to those assigned to placebo group, the reduc-
tion (37%) was nominally significant [12]. An early
meta-analysis also reported a 20% reduction in risk of
colon cancer and 19% reduction in risk of rectal cancer
associated with postmenopausal hormone therapy, and
particularly current hormone use (34% reduction of
CRC risk) [10]. These observations strongly supported
an inverse association between exogenous postmenopau-
sal estrogens and CRC risk. However, endogenous estro-
gens may have an opposite effect on CRC risk. In the
nested CRC case–control study from the WHI cohort,
circulating estradiol concentration was positively asso-
ciated with increased risk of CRC [13]. Similarly, the
New York University Women’s Health study reported a
1.8-fold increase of CRC risk in the postmenopausal
women having the highest quartile of circulating estrone
level compared with those having lowest quartile [14].
Although the exact mechanisms are unclear, several
observations may help explain the disparate results.
First, in the WHI clinical trial, estrogen plus progestin
exerted a protective role, whereas oral estrogen alone
achieved no such effect [31]. Second, the use of oral
estrogens usually couples with increased expression of
sex-hormone-binding globulin, which leads to reduced
concentrations of bioavailable estrogen [32]. Finally, oral
estrogens showed a negative correlation with the synthe-
sis and activity of insulin-like growth factor I axis com-
ponents, which have a protective role against CRC
tumorigenesis [13]. In our study, in agreement with
these previous results, we found that high circulating es-
tradiol concentrations were associated with increased
risk of CRC in men, supporting the risk effect of en-
dogenous estrogens on CRC development. Further stud-
ies to evaluate the sex-difference and dose-difference
effect of endogenous estrogens on CRC tumorigensis are
warranted.
One of the most intriguing findings in our study
was the joint effect of ESR2 rs4986938 genotype and
estradiol levels on CRC risk. Although there was no
significant interaction between rs4986938 genotypes andserum estradiol levels for CRC risk in our study (data not
shown), the joint effect was likely close to the expected
additive scale, that is, individuals with both high estradiol
level and rs4986938 risk genotypes had a significant OR
of 2.3, compared with individuals with low estradiol level
and wild-type genotype, which was higher than the sum
of ORs in those with high estradiol level only (OR, 1.1)
and in those with wild-type genotype alone (OR, 1.0).
This result supports the possible influence of interaction
between ESR2 gene and endogenous estrogens on the
risk of CRC. It is noteworthy that the biological action
of estrogens has to be through its receptors, and colon
tissue is characterized by a predominance of ERβ, the
protein encoded by ESR2 [16]. Although the mechanisms
remain largely unknown, frequent loss of ESR2 expression
in CRC tissue has been observed, suggesting involvement
of ERβ in development and progression of CRC [17,18,33].
Moreover, some ESR2 variants have been shown to alter
the function of the receptor, affecting the tissue’s re-
sponse to estrogens [34]. There is also evidence that
rs4986938 could affect RNA stability of the ESR2 gene
[35,36]. Our findings of the joint effect of rs4986938 and
estradiol levels on CRC risk and the significant associa-
tions between ESR2 SNPs and CRC risk provides sup-
porting evidence of functional potential of ESR2 gene in
estrogen-related CRC tumorigenesis, while in vivo and
in vitro research as well as evaluation in larger popula-
tion are required for further elucidation.
ESR2 rs1256049 CT/TT genotypes conferred a
reduced risk of CRC in this Han Chinese case–control
population. This is in agreement with the study of Slat-
tery et al. which evaluated ESR2 rs1256049 in a case–
control population of vast majority of Caucasian and
found that the C allele of rs1256049 conferred an
increased risk of rectal cancer among the total popula-
tion if diagnosed before 60 years of age, and an increased
risk in colon cancer if estrogen positive [25]. A study in
Japanese population, however, found an increased risk of
CRC linked with rs1256049 TT genotype [29]. The eth-
nic difference may lead to the discrepancy among these
studies. More large-scale studies in different ethnic back-
ground population are warrant to validate the potential
role of ESR2 rs1256049 in susceptibility to CRC.
There are certain limitations to our findings. First, be-
cause all patients enrolled in this study were ethnic Han
Chinese, our ability to adequately assess risk in other
ethnic populations is limited. Further studies using suffi-
cient numbers of subjects from other races and ethnic
groups are needed to extend and confirm our findings.
Second, only a limited number of candidate SNPs were
selected in this study, which is not fully representative of
the complexity of genes in the estrogen receptor path-
way. Finally, due to the nature of hospital-based case–
control study design, a potential selection bias should be
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One of the reasons for the difference between cases and
controls in smoking status could be the selection bias.
Additionally, using hospital-based controls could gener-
ate Berkson bias which might influence the frequencies
of ESR2 genotypes and the susceptibility to CRC risk.
However, the genotype frequencies in the controls did
not deviate significantly from the Hardy-Weinberg equi-
librium, thus, the selection bias may have been mini-
mized in this study.Conclusions
Our findings may support a role for estrogens in colo-
rectal tumorigenesis. We found that both serum estra-
diol and ESR2 genetic variants individually were
associated with risk of CRC. In addition, individuals with
both rs4986938 risk genotypes and high estradiol level
had a higher risk for developing CRC in men. Therefore,
the functional SNPs, hormone environmental factors,
and their interactions, may provide a new clue for indivi-
dualized evaluation CRC and offer effective prevention
strategies in the future. However, our findings need to
be validated by larger studies, and additional functional
investigations of mechanisms are warranted.
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